We propose a hybrid partial differential equation–agent-based (PDE–ABM) model to describe the spatio-temporal viral dynamics in a cell population. The virus concentration is considered as a continuous variable and virus movement is modelled by diffusion, while changes in the states of cells (i.e. healthy, infected, dead) are represented by a stochastic ABM. The two subsystems are intertwined: the probability of an agent getting infected in the ABM depends on the local viral concentration, and the source term of viral production in the PDE is determined by the cells that are infected. We develop a computational tool that allows us to study the hybrid system and the generated spatial patterns in detail. We systematically compare the outputs with a classical ODE system of viral dynamics, and find that the ODE model is a good approximation only if the diffusion coefficient is large. We demonstrate that the model is able to predict SARS-CoV-2 infection dynamics, and replicate the output ofin vitroexperiments. Applying the model to influenza as well, we can gain insight into why the outcomes of these two infections are different.
Paxlovid is a promising, orally bioavailable novel drug for SARS-CoV-2 with excellent safety profiles. Our main goal here is to explore the pharmacometric features of this new antiviral. To provide a detailed assessment of Paxlovid, we propose a hybrid multiscale mathematical approach. We demonstrate that the results of the present in silico evaluation match the clinical expectations remarkably well: on the one hand, our computations successfully replicate the outcome of an actual in vitro experiment; on the other hand, we verify both the sufficiency and the necessity of Paxlovid’s two main components (nirmatrelvir and ritonavir) for a simplified in vivo case. Moreover, in the simulated context of our computational framework, we visualize the importance of early interventions and identify the time window where a unit-length delay causes the highest level of tissue damage. Finally, the results’ sensitivity to the diffusion coefficient of the virus is explored in detail.
Constructing a comprehensive overview of any scientific field requires accurate literature selection, yet conventional keyword-based searches are susceptible to false positives. This problem is magnified in growing or interdisciplinary fields such as mathematical modeling in oncology that contain a rich but heterogeneous body of literature. Here, a generalizable, context-enriched artificial intelligence pipeline based on large language models (LLMs) curates large scientific corpora according to a user-defined field: mathematical modeling in oncology (>35k publications). Benchmarking against expert evaluation demonstrates high accuracy (ROC AUC∼0.95) and agreement with human judgement (correlation∼0.68), outperforming zero-shot LLM curation Analysis of the curated corpus (∼14k) suggests that Mathematical Oncology s distinct from either Systems Biology and Pharmacokinetics/Pharmacodynamics despite employing overlapping methods. Co-occurring citation network analysis defines nine research clusters focused on a range of applications including drug delivery, optimal control, stochastic modeling, tumor microenvironment, radiation, cancer evolution, and spatial multiscale modeling. Significance Statement: A generalizable, context-enriched artificial intelligence pipeline accurately curates large scientific corpora Analysis of the curated dataset applied to the se of mathematics n oncology provides comprehensive view of mathematical modeling in oncology across 140 years, revealing its shift from fundamental cancer biology towards therapeutic modelling.
Clonal hematopoiesis (CH) is the age-related expansion of mutated hematopoietic stem cells without other hematologic abnormalities. In patients with solid tumors, CH is associated with higher mortality and may evolve to therapy-related myeloid neoplasms; however, the mechanisms by which cancer treatments promote CH dynamics remain largely unknown. Here, we analyzed 392 serial samples from a prospective cohort of breast cancer patients and showed that cytotoxic treatments (chemotherapy ± radiation) led to strong therapeutic bottlenecks, resulting in significant reductions in hematopoietic allelic populations and differential clonal selection. CH clones that were positively selected and expanded through dose-dependent therapeutic bottlenecks frequently harbored mutations in TP53, PPM1D, SRCAP, DNMT3A, and YLPM1. Patients with positively selected CH during treatment had the shortest progression-free and overall survival compared to patients with unchanging or negatively selected CH across all therapies. These findings, corroborated in independent breast cancer and pan-cancer cohorts, provide strong evidence for clinical relevance of changes in CH during cancer treatment which may help identify patients at high risk for inferior outcomes.
Cancer stem cells (CSC) are hypothesized to promote tumor progression through innate chemoresistance and self-renewal. CSCs reside in the CD34+/CD38− immunophenotypic subpopulation of acute myeloid leukemia (AML). Isolation of CSCs from B-lymphoblastic leukemia (B-ALL) has proven difficult, and the cells of interest apparently are not isolated to the CD34+/CD38− compartment. This may be explained, in part, by temporal variations of CD34 and CD38 expression which result in stochastic cell state transitions (e.g., from CD34+/CD38+ to CD34+/CD38−). We present a mathematical model of these transitions and correlate salient findings with BCR::ABL1 status, minimal residual disease (MRD), and relapse in adult B-ALL. As the CSC hypothesis is well supported in AML, we focus on transitions to and from the hematopoietic stem cell compartment (CD34+/CD38−). Our analysis suggests the presence of dedifferentiating transitions to a CD34+/CD38− stem cell–like immunophenotype, especially in B-ALL with BCR::ABL1. In contrast, BCR::ABL1-negative patient samples have low CD34+/CD38− self-renewal rates and either high CD34+/CD38+ or CD34−/CD38+ incoming rates. High CD34+/CD38− self-renewal is also associated with positive MRD following induction chemotherapy. We find a lack of observable changes in cell state transitions between diagnosis and relapse specimens. Furthermore, simulated therapies targeting the stem cell–like compartment indicate that blocking transitions to the CD34+/CD38− state (i.e., blocking dedifferentiation) is more effective than promoting transitions from the CD34+/CD38− state toward other states (i.e., promoting differentiation) to reduce the proportion of CD34+/CD38− cells. The modeling framework used here is a novel, useful tool to infer prognosis and genotype from routine flow cytometry. Significance: Flow cytometry characterization of B-ALL samples (diagnosis, remission, and relapse) is used to parameterize a mathematical model of cell state transition rates and stratify patients for post-induction chemotherapy MRD.